1. Background {#sec1}
=============

Use of insecticide-treated nets, advances in vector control, timely malaria detection and administration of artemisinin-based combination therapy (ACT) have together contributed to reduction in the incidence of malaria from 72 to 59 cases per 1000 population between the years 2010 and 2017 worldwide ([@bib90]) (<https://www.who.int/malaria/publications/world-malaria-report-2018/en/>). Yet malaria remains a major killer with \~219 million cases and \~435,000 deaths in 2017 alone ([@bib90]) (<https://www.who.int/malaria/publications/world-malaria-report-2018/en/>). India has witnessed \~56% decline in malaria-related deaths between 2004 and 2016 but still ranks fourth in malaria incidence worldwide ([www.malariasite.com/malaria-India](http://www.malariasite.com/malaria-India){#intref0020}) (National framework malaria elimination India, 2016-2030, [@bib51]). Surveillance reports by WHO indicate that \~80% of cases in India occur in rural areas within 16 states covering the regions of East, Northeast (NE) and central India (<http://www.searo.who.int/india/topics/malaria/en/>) (National framework malaria elimination India: 2016-2030, 2015).

Despite numerous reports on the emergence of *Plasmodium falciparum* with reduced susceptibility to ACT, it remains the favored drug cocktail due to its effectiveness ([@bib50]; [@bib89]) (<https://www.who.int/malaria/publications/atoz/9789241549127/en/>). The isolation of *P. falciparum* parasites from Western Cambodia with delayed parasite clearance at day 3 (DPC3) that showed decreased susceptibility to ACT was alarming and marked the start of concern for ACT resistance ([@bib2]; [@bib19]; [@bib24]; [@bib52]; [@bib75]; [@bib77]; [@bib80]). Mutations in K13 have been studied for their association with parasites' decreased susceptibility to ACT ([@bib1]; [@bib2]; [@bib59]; [@bib68]; [@bib70]). Kelch 13 (K13) is a member of Kelch-like superfamily ([@bib2]; [@bib22]; [@bib76]) and is dimeric as per its crystal structure (Protein Data Bank ID: 4YY8). The structure of K13 has previously been analyzed for the distribution of ART resistance mutations and its dimerization interfaces ([@bib27]; [@bib67]). A previous structural exploration of K13 mutational landscape by our group revealed their partitioning into surface exposed and buried mutations ([@bib67]). However, these analyses did not draw any structural link with the proposed ART failure phenotype.

In addition to the presence of K13 mutations, the current criteria for assessment of ART resistance rely upon DPC3, parasite clearance half-life (PCHL) as well as *in-vitro* and *ex-vivo* ring stage survival assays (RSAs) (described in later sections). Interestingly, a recent study on splenectomized monkey malaria model showed equal recrudescence of ART treated *Pf* infections with strains that either harbored or not the key K13 mutation C580Y ([@bib64]). Further, the authors elegantly showed that parasite clearance time did not provide a distinct separation between the K13 C580Y mutant strain and its wild-type ([@bib64]). This study therefore re-emphasized the importance of partner drugs in ACT, and supported the view from several other studies that mutations in other genes (*dhps, dhfr, crt, mdr1, plasmepsin1*) may also contribute towards ACT failure ([@bib36]; [@bib40]; [@bib49]; [@bib57]; [@bib65]).

Aside from propelling basic research directed at identifying the molecular markers for ACT failure, the international community is also racing towards the identification of new drug targets and scaffolds to cover for the eventual emergency of complete ACT failure ([@bib10]; [@bib18]; [@bib32]; [@bib31]; [@bib33]; [@bib93], [@bib94]). Over the past decade, numerous new drug targets have been identified, probed and then validated. Drug repurposing methodologies and structure-based conservation techniques that target invariant parasite house-keeping proteins may lead to novel foci for drug development ([@bib18]; [@bib32]; [@bib31]; [@bib33]; [@bib58]; [@bib93], [@bib94]). However, till then, surveillance and containment of mutant *P. falciparum* parasites that show decreased susceptibility to ART/ACT are of primary importance. The location and timing of efforts at containment likely need to be centered on India as well as the country nestles in the traditional path of anti-malarial drug resistance spread -- i.e. from East Asia to Africa ([@bib5]; [@bib17]; [@bib46]).

Our analyses here provide a summation of K13 mutant data from South Asia with a focus on India. It is apparent that an integrated framework of surveillance and validation is required for tracking possible ART/ACT resistance in India. We emphasize the cataloging of single nucleotide polymorphisms (SNPs) on a whole genome level of parasites from malaria endemic regions that can then provide a genomic atlas. This will contribute towards both surveillance and containment of ART resistance/ACT failure.

2. Identification of ART/ACT failure {#sec2}
====================================

ART is highly active against all intra-erythrocytic stages of *Plasmodium* spp. and causes up to \~10,000 fold reduction in parasites within the first 48 h of administration ([@bib19]; [@bib83]; [@bib53]; [@bib88]). Since ART has a short plasma half-life it is administered in combination with long-acting partner drugs that clear the remaining parasite biomass ([@bib19]; [@bib83]; [@bib53]; [@bib88]). The standard assay for validating ART resistance relies on the identification of parasites with reduced susceptibility to ACT (via DPC3) and the presence of mutations in K13 protein ([@bib19]; [@bib83]; [@bib53]; [@bib88]). Resistance to partner drugs is assessed by tracking any recrudescence of infection at day 28 or 42, depending on the half-life of the partner drug ([@bib15]; [@bib34]; [@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). Delayed parasite clearance (DPC) is expressed as PCHL, which is determined by plotting log-linear parasite clearance curve ([@bib20]). The curve is drawn between log parasitemia (calculated every 6 h from the beginning of medication till no parasites are detected) against time interval ([@bib84]). PCHL is then calculated via slope of the linear part of parasite clearance curve using the parasitemia clearance estimator (PCE) software (<https://www.wwarn.org/pce/>) ([@bib25]; [@bib84]). PCHL of ≥5 h after ACT administration is defined as ART resistance relative to the PCHL values determined for ART sensitive isolates ([@bib3]; [@bib22]; [@bib85]). In addition, parasite survival rate of ≥1% via *in-vitro* RSAs is also used as marker for possible ART resistance ([@bib87]). For *in-vitro* RSAs ~(0-3h)~, cultured synchronized ring stage parasites are subjected to a dose of 700 nM of dihydroartemisinin (DHA) for 6 h and parasite numbers are estimated after 66 h of growth ([@bib2]; [@bib88], [@bib87]). The ratio of number of parasites surviving DHA to parasites surviving DMSO (control) is used to calculate percent survival ([@bib2]; [@bib88], [@bib87]). In an alternative version of RSA, called *ex-vivo* RSA, *P. falciparum* isolated directly from patients can be used to distinguish between fast and slow clearing parasites after ACT administration ([@bib87]). A malaria endemic area is considered for ART resistance if either 10% or more of its patients harbor parasites with PCHL ≥5 h or 10% or more of the patients show DPC3 after ACT administration ([@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). Further, a malaria endemic region is confirmed for ART resistance if both of the above parameters are met along with detection of K13 *P. falciparum* mutants ([@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). These are the current WHO standards for annotation of ART resistance. However, the landscape of K13 mutants reported from South Asia, and particularly India, presents an interesting scenario. For instance, there is discordance in the annotation of ART resistance (using DPC3, PCHL and/or RSA) for the same K13 mutants (E252Q, E270K, P441L, G538V and A675V) ([@bib6]; [@bib48]; [@bib87]). This situation therefore necessitates new integrated efforts to annotate whether a given clinical isolate is indeed resistance to ART or not. It is also important to dissect whether the same K13 mutants behave differently (in context of ART resistance) depending on their clinical/geographical/genomic background.

3. On K13 as a marker of artemisinin resistance {#sec3}
===============================================

Analysis of *P. falciparum* mutants with reduced susceptibility to ACT via genome-wide association studies (GWAS), along with gene manipulation studies, have indicated an association between mutations in K13 and altered PCHL/parasite survival in RSAs ([@bib2]; [@bib9]; [@bib26]; [@bib70]; [@bib72], [@bib71]; [@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). K13 protein is a 726 amino-acid member of Kelch-like superfamily with a C-terminal six-blade β-propeller domain, a *Plasmodium*-specific N-terminal domain and a BTB/POZ domain ([@bib2]; [@bib22]; [@bib67]; [@bib76]). K13 exists as a dimer as per its deposited crystal structure (PDB ID: [4YY8](pdb:4YY8){#intref0060}). K13 has been analyzed for distribution of resistance mutations and for its dimerization interfaces ([@bib27]; [@bib67]). To date, no cohesive or testable hypothesis links K13 mutations to ART failure. A recent study has suggested the use of protein structural modelling to generate testable predictions to determine the impact of *Pf* K13 mutations on *in vivo* (and potentially *in vitro*) ART susceptibility ([@bib28]). Independently, *P. falciparum* K13 down-regulation has been linked with increased parasite clearance times thereby suggesting that reduced *Pf* K13 transcriptional response may be a first step towards ART resistance ([@bib66]).

More than 200 non-synonymous mutations have been identified in K13 protein from *P. falciparum* strains ([@bib22]; [@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). While most mutations occur at low prevalence and have uncertain functional significance, fifty of these were assessed for reduced susceptibility to ACT/ART resistance using DPC3, PCHL and/or RSA ([@bib11]; [@bib23]; [@bib39]; [@bib54]; [@bib64]; [@bib78]; [@bib92]) ([Fig. 1](#fig1){ref-type="fig"}a and b). Of these, only nine mutations have been validated for ART resistance *ex-vivo* (F446I, N458Y/I, M476I/V, Y493H, R539T, I543T, P553L, R561H, C580Y) ([Fig. 1](#fig1){ref-type="fig"}a (in red)) ([@bib6]; [@bib26]; [@bib70]; [@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). A further eleven mutations have either been marked as possible candidates or remain associated but have not been validated for ART resistance (P441L, G449A, C469Y, A481V, N537I, G538V, V568G, P574L, N672S, F673I, A675V) ([Fig. 1](#fig1){ref-type="fig"}a). Although C580Y mutation remains a dominant marker for ART/ACT resistance across SEA, a recent study has suggested that parasite clearance time does not distinguish between the ART sensitive and ART resistant C580Y strains ([@bib64]). In this work, the authors showed that IC~50~ values of DHA were at similar nM levels for both C580 (wildtype) and C580Y mutant strain (a validated K13 mutant for ART resistance) ([@bib64]). However, it is noteworthy that the splenectomized *Aotus* monkey, which is a nonhuman primate model for malaria, is semi-immune and therefore an artificial system. This work and other studies have nonetheless reinforced the need for a more holistic approach to study ART resistance in the field. Such efforts may minimally include validation of clinical data, assessment of reduced drug sensitivity via DPC3 and PCHL, study of corresponding RSAs and possibly genome wide association studies (GWAS) to determine SNPs across the parasite genome.Fig. 1Geographical distribution of K13 domain mutations in South Asia. **a)** K13 mutations that are either validated (red) or are associated/candidates (blue) for ART resistance are shown. Pie chart depicts K13 mutant distribution based on their status i.e. validated (red), candidates (blue) or uncategorized/un-associated (grey) as defined by the World Health Organization (WHO) in context with ART resistance. **b)** Tabular representation of the K13 mutations identified from different countries of South Asia. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

4. Landscape of K13 mutations {#sec4}
=============================

SEA is considered an epicenter for emergence and spread of malaria drug resistance ([@bib46]; [@bib45]; [@bib63]; [@bib82]) ([Fig. 1](#fig1){ref-type="fig"}a). Mutations in K13 were first reported from West Cambodia in 2008 and C580Y, Y493H and R539T were the most prevalent then (\>5% frequency) ([@bib2]). These along with other K13 protein mutants either spread slowly or emerged independently in various other SEA countries - Vietnam, Thailand and Myanmar -- and eventually C580Y became the most dominant (75--90%) mutant in a span of ten years ([@bib2]; [@bib35]; [@bib37]; [@bib59]; [@bib61]; [@bib72]; [@bib73]; [@bib80]). However, reports from China and China-Myanmar border showed the presence of a different set of K13 mutations with F446I being the most dominant followed by R539T, P574L, N458Y, R561H and A676D ([@bib24]; [@bib29]; [@bib80]; [@bib92]). It has been suggested that the presence of K13 mutants at China-Myanmar border may enable spread of above strains to bordering NE states of India ([@bib77]). This situation therefore calls for stringent monitoring of K13 mutant parasites isolated from malaria-infected patients in NE (and mainland) India. Recent studies from India have identified fourteen K13 mutations in parasites isolated from malaria infected Indian patients. These mutations are: K189T, F446I, A481V, G533 A/S, R539T, S549Y, R561H, A578S, M579T, G625R, N657H, N672S, A675V and D702N ([Fig. 1](#fig1){ref-type="fig"}b & [Table 1](#tbl1){ref-type="table"}) ([@bib12], [@bib13]; [@bib43], [@bib42]; [@bib44]). These mutations were isolated from the states of Assam, Tripura, Mizoram, Arunachal Pradesh, West Bengal, Madhya Pradesh and Chhattisgarh ([@bib12], [@bib13]; [@bib43], [@bib42]; [@bib44]). A number of studies have failed to show a significant co-relation between these K13 mutants and their propensity for ACT failure in Indian population ([@bib4]; [@bib12]; [@bib41]; [@bib43], [@bib42], [@bib44]). However, a more recent study from India identified a novel *Pf* mutation -- G625R - and a previously validated mutation -- R539T - from malaria-infected patients in Eastern India; each is associated with ART resistance based on DPC3 (presence of parasite at day 3), PCHL\> 5 h and RSA~0-3hr~ (parasite survival rate, \>1%) criteria ([@bib13]). This report on the identification of G625R and R539T and their association with ART resistance, along with detection of early treatment failure, has raised concerns in the malaria research community in India ([@bib62]). While Das et al. emphasize that the criteria required to define ART resistance are met, the points raised by the malaria research community in India are also valid ([@bib62]). Intriguingly, another study from India by Chakrabarti et al. in 2019 showed reduced sensitivity to DHA ([@bib8]). Further to this, the authors reported A675V mutation within the Kelch propeller domain (RSA of 2%). These cases from India therefore present an opportunity for adoption of a more robust and thorough approach for annotating field strains as ART/ACT resistant or otherwise.Table 1K13 mutations from Indian patients.Table 1MutationCity (State)ReferenceK189TLunglei (Mizoram)\
Gomati (Tripura)[@bib43]F446IChanglang (Arunanchal Pradesh)[@bib43]A481VChanglang (Arunanchal Pradesh)[@bib12]G533 A/SGomati (Tripura)[@bib42]R539T- (West Bengal)[@bib13]S549YJalpaiguri (West Bengal)[@bib42]R561 H/CChanglang (Arunanchal Pradesh)[@bib42]A578SLunglei (Mizoram)([@bib43], [@bib42])M579 T/HBastar (Chattisgarh)\
Balaghat, Annupur, Jhabua (Madhya Pradesh)[@bib44]G625R(West Bengal)[@bib13]N657HBalaghat, Annupur (Madhya Pradesh)[@bib44]N672S- (West Bengal)[@bib13]A675V- (Arunanchal Pradesh and Assam)[@bib12]D702N- (Arunanchal Pradesh)[@bib12]

5. Structural analysis of K13 mutations {#sec5}
=======================================

We mapped fourteen mutations observed in Indian isolates on the K13 crystal structure (PDB ID: 4YY8) ([Fig. 2](#fig2){ref-type="fig"}a). Of these, eleven mutations - G533A, R539T, S549Y, R561H, A578S, M579H, G625R, N657H, N672S, A675V and D702N - are exposed while two - F446I and A481V -- are in the central protein cavity ([Fig. 2](#fig2){ref-type="fig"}a). Of the fourteen, six (G533A, A578S, M579H, G625R, N672S and A675V) are located on the small channel that runs through the center of K13 ([Fig. 2](#fig2){ref-type="fig"}a), and as K189T/I205T are located outside the propeller domain their significance is especially unclear. Furthermore, three K13 mutations -- F446I, R539T and R561H -- have been categorized as validated for ART resistance in SEA countries by WHO ([Fig. 1](#fig1){ref-type="fig"}) ([@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). Of these three, a recent report has suggested that R539T from (two) Indian isolates showed signs of ART resistance and early treatment failure as assessed by DPC3, PCHL and RSAs) ([@bib13]). In yet another contrary finding, the WHO-validated F446I and R561H do not seem to affect treatment when isolated from Indian patients (as per DPC data alone) ([@bib43]; [@bib13]).Fig. 2Structural mapping of K13 mutations found in India. **a)** Orthogonal views of single nucleotide polymorphisms (SNPs) where validated K13 mutations are in red, associated/candidate mutations are in blue and those from India are in green (PDB ID: [4YY8](pdb:4YY8){#intref0090}). **b)** Mapping of three sets of double mutations found in K13 along with validated C580Y mutation (in green) . As H136N does not map on K13 propeller domain it is not shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

Strikingly, our structural mapping of the fourteen Indian mutations does not offer any coherent explanation for their contribution towards ART resistance ([Fig. 2](#fig2){ref-type="fig"}a). The mutations are spatially spread over K13 propeller domain and do not congregate to any particular surface or groove ([Fig. 2](#fig2){ref-type="fig"}a). There seem to be no clear links between the sets of K13 mutations and their association with ART failure. This suggests that the ART-K13 linkage for drug resistance is not evidentially and structurally robust. More intriguingly, a few Indian K13 mutations (R561H, F446I, A481V, A675V) display contradictory phenotypes in context of ACT failure when compared to data from SEA. For instance, the mutation R561H was previously reported in SEA and sub-Saharan Africa and displays PCHL ≥5 h ([@bib23]). The same mutation was isolated from a malaria patient in Changlang district of Arunachal Pradesh, India but was not associated with ACT failure as estimated by monitoring treatment failure at day 28 ([@bib42]). The F446I mutation (buried) has been isolated from a patient in Changlang district of Arunachal Pradesh (close to Myanmar, [Fig. 3](#fig3){ref-type="fig"}) ([@bib43]) and it is also highly prevalent at the China-Myanmar border (in Northeast Myanmar and in Yunnan province, China) ([@bib80]). However, F446I shows no association with ACT failure in India as estimated by lack of treatment failure at day 28 ([@bib43]) as in the case for samples from China-Myanmar border (as per RSAs) ([@bib92]). However, the F446I mutation has been associated with DPC3 in Central and Northern Myanmar ([@bib78]). The above two examples of R561H and F446I highlight lack of coherence in association between K13 SNPs and treatment failure when isolates from different geographical regions are compared. These contradictory phenotypes also suggest that reliance on K13 protein as a marker for ACT failure may be reconsidered.Fig. 3Kelch 13 (K13) mutations in India. Geographical distribution of Kelch 13 (K13) mutations in *Plasmodium sp.* clinical isolates. The states with highest number of malaria cases reported are shown based on their ranking (i.e., Odisha followed by Meghalaya, Mizoram, Jharkhand, Chattisgarh and Rajasthan) along with the K13 mutations categorized based on validated (in red), candidates/associated (in blue) and putative (in grey) for ART resistance. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

In context of India, only the G533A mutation, identified from one isolate in Gomati district of Tripura (bordering Bangladesh), has been claimed for treatment failure at day 28 (no DPC3, PCHL or RSA data are available for this sample) ([@bib42]). However, as noted earlier, treatment failure cannot be attributed to ART resistance alone and could be due to resistance towards the partner drug or due to several other factors ([@bib36]; [@bib65]). The most frequent mutations observed amongst Indian isolates include K189T (Tripura and Mizoram - bordering Bangladesh) ([@bib43]), A481V (Arunachal Pradesh) ([@bib12]) and A675V (from Assam and Arunachal Pradesh) ([@bib12]). Although the role of K189T in ACT resistance is yet to be established, A481V and A675V have been categorized as potential candidates for ART resistance ([@bib91]) (<https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>). Once again, there is lack of agreement between WHO declared annotation of A481V and A675V mutants ([@bib12]). A novel mutation - D702N -- has been observed amongst isolates from Arunachal Pradesh ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}) ([@bib12]). It has been postulated that D702N mutation emerged independently and therefore validation assays are required to unlock its role in ACT resistance, if any ([@bib12]). Two additional novel mutations - M579T and N657H - have been identified from different districts of Madhya Pradesh in India ([Fig. 3](#fig3){ref-type="fig"}). Though M579T was found to occur alone among 1.5% of isolates, N657H was observed along with M579T in 37% of isolates; however, none of these isolates were found to be associated with DPC3 ([@bib4]; [@bib44]). The above double mutant (M579T/N657H) parasites could be due to infection of multiple parasite clones or due to the presence of double mutation in a single parasite line (discussed later). The structural mapping of M579T and N657H reveals that these residues reside on the blades IV and VI respectively. Further, these two mutations are located on the small channel that runs through the center of K13 ([Fig. 2](#fig2){ref-type="fig"}b). M579T is proximal to the well-studied C580Y while N657H resides on blade V within the central channel ([Fig. 2](#fig2){ref-type="fig"}b).

Identification of S549Y mutation from Jalpaiguri district of West Bengal (bordering Bhutan and Bangladesh, near Assam) ([Fig. 3](#fig3){ref-type="fig"}) could be indicative of slow migration of mutant parasites from NE to the mainland, or of another independent origin ([@bib42]). S549Y remains to be studied for ART resistance in SEA and is uncategorized as yet. Further, the mutation A578S has been identified in Bangladesh with no reported cases of ACT failure or ART resistance ([@bib47]; [@bib69]). A retrospective study conducted on 68 malaria patients showed day three parasitemia/DPC3 amongst 57% of the patients (as monitored by microscopic examination) post ACT (Artesunate + Sulfadoxine-Pyrimethamine administration ([@bib43]). However, this study lacks corroborative markers on K13 mutations and/or PCHL/RSA data ([@bib41]).

Studies on K13 mutations isolated from patients reveal dominance of single mutations and double ones are rare ([Table 2](#tbl2){ref-type="table"} & [Fig. 2](#fig2){ref-type="fig"}b) ([@bib2]; [@bib3]; [@bib44]; [@bib48]; [@bib55]; [@bib74]; [@bib75]; [@bib78]; [@bib80]). Nonetheless, double mutations of H136N-C580Y and P574L-F446I have been identified from single parasite clones isolated in China (1/191) and Cambodia (2/157) respectively ([@bib48]; [@bib80]). K13 double mutants were also seen in one clinical isolate from Mali and four from Senegal but these were attributed to infection by two parasite clones ([@bib55]; [@bib74]) ([Table 2](#tbl2){ref-type="table"} & [Fig. 2](#fig2){ref-type="fig"}b).Table 2Clinical isolates with K13 double mutants.Table 2MutationsLocationIsolatesReferenceP574L and F446IChina-Myanmar border1/191[@bib80]M579T and N657HMadhya Pradesh50/186[@bib44]H136N and C580YCambodia2/36[@bib48]

6. K13-independent artemisinin resistance {#sec6}
=========================================

ART resistance in the absence of K13 mutations has been reported ([Table 3](#tbl3){ref-type="table"}) ([@bib2]; [@bib7]; [@bib14]; [@bib16]; [@bib38]; [@bib40]; [@bib48]; [@bib64]; [@bib71], [@bib72]; [@bib81]). Identification of four parasite isolates from Cambodia with wild type K13 protein but RSA ≥0.8% had suggested K13-independent ART resistance ([@bib48]). Indeed, genomic analysis performed on both sensitive and resistant isolates have identified 37 novel mutations spread over nineteen non K 13 genes, with eleven present in the four isolates without K13 mutations with RSA ≥0.8% ([@bib48]). Maximum mutations were identified in phosphoinositide 3-kinase (PI3K) and in multidrug resistance protein 1/2 (mdr1/2) ([@bib48]). In another study, three cases of treatment failure at days 21 and 28 were reported from Bastar district of Chhattisgarh in India but all three-harbored wild-type K13 protein ([@bib4]). However, recrudescence was confirmed using only two of the three recommended markers ([@bib4]). Further, SNPs outside chromosome 13 have also been weakly associated with ART resistance ([@bib2]; [@bib7]; [@bib38]; [@bib40]; [@bib71]; [@bib81]). Thus, it is imperative to understand if mutations in genes other than K13 contribute towards emergence and spread of ACT failure ([@bib7]; [@bib40]; [@bib86]).Table 3Wild type K13 with postulated Artemisinin (ART) resistance.Table 3LocationIsolatesAssessment criteriaReferenceOdisha, India3DPC3 +ve[@bib4]Uganda3*Ex-vivo* RSA \>10%([@bib96])Asia wide study21PCHL \> 5 h[@bib3]China-Myanmar border1*Ex-vivo* RSA \>14%[@bib92]Cambodia4*In-vitro* RSA \> 0.8%[@bib48]

A GWAS performed by Miotto *et*. al has earlier suggested that mutations in multidrug resistance protein 2 (mdr2, T484I), ferredoxin (fd, D193Y), apicoplast ribosomal protein S10 (arpS10, V127M) and chloroquine resistance transporter (crt, I356T and N326S) may form a genetic background on which mutations in K13 emerge ([@bib40]). Mutations in fd, arsp10 and mdr2 genes from ART resistant K13 mutant parasites have also been isolated from Myanmar ([@bib21]; [@bib54]). Surprisingly, D193Y and V127M mutations (in ferredoxin and ribosomal protein respectively) were observed in only three 'R539T' K13 mutant isolates from China-Myanmar border whereas both D193Y and V127M showed high association with the 'R539T' K13 mutant isolated from Thai-Cambodia border ([@bib92]). Thus it was suggested that SNP analysis of fd and arpS10 genes may shed additional light on the lineage of mutant haplotypes ([@bib92]). Studies have also indicated weak association of SNPs in nuclear LIM-interactor interacting factor (NIF4)-like phosphatase ([@bib40]; [@bib81]), and 'T38N' change in pfatg18 to be associated with ART resistance ([@bib81]). Pfatg18 has also been proposed as a potential target for ART resistance ([@bib21]). Various DNA repair genes including mlh1, pms1 and exo1 are overexpressed in ART resistant parasites and thus considered to be associated with ART resistance ([@bib38]). The genome analysis of parasites with K13 mutations has revealed yet another Kelch-domain containing protein Kelch10 (K10) that may epistatically modulate ART resistance phenotype ([@bib7]; [@bib86]). The mutation P623T in K10 was shown to increase parasite clearance rates in C580Y and E252Q K13 mutant strains ([@bib7]). Further, mutations in actin-binding protein coronin have been shown to reduce parasite susceptibility to ART *in-vitro* ([@bib16]). The above studies therefore present a varied landscape of alternations in the genomes of resistant parasites isolated from field, and offer no clear causal relationship for ART resistance with a one-gene locus.

7. Surveillance strategies for tracking ACT failure {#sec7}
===================================================

Isolation of K13 mutant parasites from various Indian states highlights the need to understand their co-relation with ART resistance/ACT failure. This requires robust surveillance and quick detection of K13 mutant parasites, especially amongst the populations living in NE of India. The identification of K13-independent isolates which may show treatment failure is also equally vital. Hence, to cover these issues holistically, we propose that new surveillance strategies be devised based on state-of-the-art molecular technologies. A few possibilities are:1.GWAS: It will provide a complete readout of the genomic content of field parasites and will contribute to the growing worldwide genome database ([@bib7]; [@bib40]; [@bib72]). Study of microsatellite loci along with SNPs in genes such as fd, crt, mdr2 and arps10 will contribute towards dissecting the lineages of these mutations in field isolates. Such studies will also shed light on the phylogenetic relationships between field strains ([@bib30]; [@bib40]; [@bib73]; [@bib75]).2.Implementation of filter paper based blood sample collection methodology for genomic surveillance ([@bib56]).3.Establishment of biobanks for maintaining stocks of parasites isolated from various Indian regions spanning the country so that geographical linkages can be drawn for migration of resistant parasite strains.4.4. Health care worker training on the use of new web tools for analysis of parasites including the PCE developed by World Wide Antimalarial Resistance Network and 'Shiny web' (available at 'bit.ly/id_artemisinin_resistance') which estimates PCHL ([@bib25]; [@bib79]). Another software called Genome-wide mixed-model association (GEMMA) and/or PLINK could be used for establishing co-relations between mutations in K13 and DPC3 data ([@bib60]; [@bib81]; [@bib95]).

8. Concluding remarks {#sec8}
=====================

Artemisinin-based combination therapy (ACT) is a highly efficacious treatment for malaria but emergence and spread of *P. falciparum* parasites with reduced susceptibility to ACTs is threatening malaria control. Stringent monitoring of ART resistance/ACT failure, possibly via development of rapid and economical surveillance tools, as well as systematic cataloguing of epidemiological, clinical (DPC3, PCHL, RSA) and genomic data (GWAS) is hence of utmost importance. We propose emphasis on whole genome sequencing of field strains so that data obtained can be integrated with genomic data from South Asia and African isolates. Further, in light of emerging reports on K13 mutants from various regions in India, it is imperative that India employ the latest technologies for annotation of any treatment failure cases. There is thus an urgent need to track ART resistance/ACT failure via clinical, epidemiological and genomic screenings. Such assessments may include 1) DPC3, 2) PCHL, 3) *in-vitro* and *ex-vivo* RSAs and 4) GWAS to identify mutations. These efforts may help in surveillance and containment of ART resistance/ACT failure in India, and may contribute towards integration with worldwide databanks that are monitoring the growth of drug resistance in malaria.
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